Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-
2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease …

Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …

Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …

Abstract The International Society for Influenza and other Respiratory Virus Diseases held its
6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13–15, 2018 …

To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

Emergence and re-emergence of respiratory virus infections represent a significant threat to
global public health, as they occur seasonally and less frequently (such as in the case of …

Although the development and clinical application of SARS-CoV-2 vaccines during the
COVID-19 pandemic demonstrated unprecedented vaccine success in a short time frame, it …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and
mortality rates. Currently, the influenza drugs recommended by the FDA are oseltamivir …

Vaccines remain the best measure to reduce total influenza burden. However, presently
available influenza vaccines have some limitations that cause a reduced efficacy compared …